

Financial news for CMRX dated on 2020-05-07: Chimerix Q1 EPS \$(0.170) Up From \$(0.350) YoY

Financial news for CMRX dated on 2020-04-29: Chomerix shares are trading higher after the company announced it has initiated its Phase 2/3 study of DSTAT in acute lung injury for patients with severe coronavirus.

Financial news for CMRX dated on 2020-04-29: Chimerix Reports Initiation Of Phase 2/3 Study Of DSTAT In Acute Lung Injury For Patients With Severe Coronavirus Infection

Financial news for CMRX dated on 2020-04-28: Chimerix shares are trading higher after the company received FDA clearance for rolling submission of New Drug Application for Brincidofovir as a medical countermeasure for smallpox.

Financial news for CMRX dated on 2020-04-28: Chimerix Receives FDA Clearance For Rolling Submission Of New Drug Application For Brincidofovir As A Medical Countermeasure For Smallpox

Financial news for CMRX dated on 2020-02-25: Chimerix Q4 EPS \$(0.06) Beats \$(0.17) Estimate

Financial news for CMRX dated on 2019-12-10: Chimerix Presents Updated Results From Phase 2 Clinical Trial Of DSTAT In Refractory Myelodysplastic Syndrome And Acute Myeloid Leukemia At American Society Of Hematology Annual Meeting

Financial news for CMRX dated on 2019-11-05: Chimerix Q3 EPS \$(0.15) Beats \$(0.22) Estimate, Sales \$1.958M Beat \$900K Estimate

Financial news for CMRX dated on 2019-08-08: Chimerix Announces Co. Is Finalizing Animal Studies Of Brincidofovir As Smallpox Medical Countermeasure For Planned NDA

Financial news for CMRX dated on 2019-08-08: Chimerix Q2 EPS \$(0.35) Beats \$(0.37) Estimate, Sales \$1.438M Beat \$1.15M Estimate; Phase 3 Trial Of Cx-01 In Front-Line Acute Myeloid Leukemia Planned To Initiate In Mid 2020

Financial news for CMRX dated on 2019-07-31: Chimerix Announces Exclusive Worldwide License Of Phase 3 Ready CX-01 For Development In Acute Myeloid Leukemia

Financial news for CMRX dated on 2019-05-09: Chimerix Restructuring To Reduce Workforce By More Than 50%, Maintaining Key Capabilities And Preserving Capital For New Programs

Financial news for CMRX dated on 2019-05-09: Chimerix Reports Positive Top-Line Survival Data From Pivotal Mouse Study As Key Milestone On Path To Smallpox Regulatory Submission; Plan To Focus On Execution Of Smallpox Program, Halting All Other Brincidofovir Development Activities

Financial news for CMRX dated on 2019-05-09: Chimerix Q1 EPS \$(0.35), Inline, Sales \$2.356M Beat \$1.5M Estimate

Financial news for CMRX dated on 2019-04-08: Chimerix Names Michael Sherman CEO, Michael Andriole Chief Business Officer

Financial news for CMRX dated on 2019-03-06: Citigroup Maintains Neutral on Chimerix, Lowers Price Target to \$2

Financial news for CMRX dated on 2019-03-05: Chimerix Q4 EPS \$(0.29) Beats \$(0.35) Estimate, Sales \$4.864M Beat \$880K Estimate

Financial news for CMRX dated on 2019-02-22: Chimerix To Present Results From Post-Hoc Analysis Of Phase 3 Study Transplantation And Cellular Therapy Meetings Of ASBMT And CIBMTR 2019

Financial news for CMRX dated on 2019-02-06: Chimerix Reports Pres, CEO M. Michelle Berrey To Step Down; W. Garrett Nichols, Timothy Trost, Michael Alrutz Named To Newly-Created Office Of The CEO On Interim Basis

Financial news for CMRX dated on 2018-12-20: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018

Financial news for CMRX dated on 2018-12-17: Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018

Financial news for CMRX dated on 2018-11-08: Chimerex, Inc. Q3 EPS \$(0.33) Beats \$(0.42) Estimate, Sales \$369K Miss \$970K Estimate

Financial news for CMRX dated on 2018-10-29: Stocks Which Set New 52-Week Low Friday, October 26th

Financial news for CMRX dated on 2018-10-24: Stocks Which Set New 52-Week Low Yesterday, October 23rd

Financial news for CMRX dated on 2018-10-23: '6 kids dead, 12 sick in viral outbreak at New Jersey rehabilitation center' -ABC 7 NY

Financial news for CMRX dated on 2018-10-23: Stocks Which Set New 52-Week Low Yesterday, October 22nd

Financial news for CMRX dated on 2018-10-05: Chimerix To Highlight Results From Multiple Ascending Dose Study Of IV Brincidofovir At IDWeek

Financial news for CMRX dated on 2018-09-14: Stocks Which Set New 52-Week Low Yesterday, September 13th

Financial news for CMRX dated on 2018-09-13: Stocks Which Set New 52-Week Low Yesterday, September 12th

Financial news for CMRX dated on 2018-09-10: Stocks Which Set New 52-Week Low Friday, September 7th

Financial news for CMRX dated on 2018-09-07: Stocks Which Set New 52-Week Low Yesterday, September 6th

Financial news for CMRX dated on 2018-09-05: Stocks Which Set New 52-Week Low Yesterday, September 4th

Financial news for CMRX dated on 2018-08-17: Stocks Which Set New 52-Week Low Yesterday, August 16th

Financial news for CMRX dated on 2018-08-16: Stocks Which Set New 52-Week Low Yesterday, August 15th

Financial news for CMRX dated on 2018-08-08: Chimerix Q2 EPS \$(0.39) Beats \$(0.44) Estimate, Sales \$1.193M Beat \$950K Estimate

Financial news for CMRX dated on 2018-08-07: Stocks Which Set New 52-Week Low Yesterday, August 6th

Financial news for CMRX dated on 2018-06-12: Chimerix Reports Discovery, Demonstration Of Preclinical Activity Which Supports Ongoing Phase 1 Study Of New Antiviral Treatment, Prevention Of Norovirus

Financial news for CMRX dated on 2018-06-07: Chimerix Reports Received Orphan Drug Designation For Brincidofovir For Treatment Of Smallpox

Financial news for CMRX dated on 2018-06-06: Traders Circulating Chimerix FDA Document Showing Orphan Designation For brincidofovir

Financial news for CMRX dated on 2018-06-05: Chimerix To Address Congressional Subcommittee In Support Of Reauthorization Of Pandemic And All-Hazards Preparedness Act (PAHPA)

Financial news for CMRX dated on 2018-05-07: Chimerix Q1 EPS \$(0.42) Beats \$(0.43) Estimate, Sales \$790K Miss \$1.1M Estimate

Financial news for CMRX dated on 2018-03-29: Chimerix Names Martha Demski Chair

Financial news for CMRX dated on 2018-03-01: Chimerix Reports Q4 EPS \$(0.41) vs \$(0.47) Est., Sales \$1.8M vs \$870K Est.

Financial news for CMRX dated on 2018-02-14: JP Morgan Downgrades Chimerix to Underweight

Financial news for CMRX dated on 2018-02-02: H.C. Wainwright Initiates Coverage On Chimerix with Buy Rating, Announces \$10.00 Price Target

Financial news for CMRX dated on 2018-01-05: Chimerix Reports Initiation Of AdAPT Study For Oral Brincidofovir, Advances IV Brincidofovir To Patient Studies

Financial news for CMRX dated on 2017-11-08: Chimerix Reports Q3 EPS \$(0.37) vs \$(0.43) Est., Sales \$897K vs \$850K Est.

Financial news for CMRX dated on 2017-08-07: Chimerix Q2 EPS \$(0.36) vs \$(0.41) Est., Sales \$675K vs \$1.19M Est.

Financial news for CMRX dated on 2017-05-09: Chimerix Q1 EPS \$(0.38) vs \$(0.36) Est, Sales \$1.08M vs \$1.42M Est

Financial news for CMRX dated on 2017-03-02: Chimerix Reports Q4 EPS \$(0.32) vs. \$(0.37) Est.

Financial news for CMRX dated on 2017-02-22: UPDATE: Chimerix Says 'Mortality rates were lower in pediatric patients than in adult patients'

Financial news for CMRX dated on 2017-02-22: Chimerix Reports Final Data from Advise Trial of Brincidofovir: 'Results show higher survival rate in adenovirus-infected patients with a virologic response'

Financial news for CMRX dated on 2017-02-22: Chimerix Reports Final Data Of Brincidofovir, Results Show Higher Survival Rate In Adenovirus-Infected Patients With Virologic Response To Brincidofovir

Financial news for CMRX dated on 2016-02-23: Barclays Downgrades Chimerix to Equal-weight, Lowers PT to \$6.00

Financial news for CMRX dated on 2016-02-22: Morgan Stanley Downgrades Chimerix to Underweight, Lowers PT to \$5.00

Financial news for CMRX dated on 2016-02-22: Citigroup Downgrades Chimerix to Neutral

Financial news for CMRX dated on 2015-12-29: Empire Asset Management Terminates Sell Rating on Chimerix, Was Only Firm With A 'Sell' Ratings

Financial news for CMRX dated on 2015-12-29: FBR Capital Downgrades Chimerix to Market Perform, Lowers PT to \$14.00

Financial news for CMRX dated on 2015-12-29: JP Morgan Downgrades Chimerix to Neutral, Lowers PT to \$15.00, Sees Investors 'assigning little credit to brincidofovir'

Financial news for CMRX dated on 2015-12-28: Cowen & Company Downgrades Chimerix to Market Perform, Lowers PT to \$8.00

Financial news for CMRX dated on 2015-12-28: Brean Capital Downgrades Chimerix to Hold

Financial news for CMRX dated on 2015-12-17: UBS Initiates Coverage on Chimerix at Buy, Announces \$55.00 PT

Financial news for CMRX dated on 2015-12-01: Janney Capital Earlier Initiated Coverage on Chimerix at Neutral, Announced \$50.00 PT

Financial news for CMRX dated on 2015-10-05: Morgan Stanley Downgrades Chimerix to Equal-weight, Lowers PT to \$50.00

Financial news for CMRX dated on 2015-06-10: Chimerix Prices 3.775M Share Offering @\$39.75/Share

Financial news for CMRX dated on 2015-03-04: Barclays Initiates Coverage on Chimerix at Overweight, Announces \$55.00 PT

Financial news for CMRX dated on 2015-02-26: Chimerix Sees Full Enrollment of Suppress Trial in Summer 2015

Financial news for CMRX dated on 2015-02-03: JP Morgan Initiates Coverage on Chimerix at Overweight, Announces \$51.00 PT

Financial news for CMRX dated on 2014-12-18: Chimerix, ContraVir Announce Strategic Collaboration on Antiviral Drug Candidate CMX157

Financial news for CMRX dated on 2014-11-07: Chimerex, Inc. Reports Q3 EPS of \$(0.47); Revenue of \$1.19M

Financial news for CMRX dated on 2014-10-08: Chimerix Announces Brincidofovir Shows Potential Survival Benefit in Adenovirus Infection

Financial news for CMRX dated on 2014-10-02: UPDATE: Piper Jaffray Boosts Target on Chimerix from \$33 to \$37, Maintains Overweight

Financial news for CMRX dated on 2014-08-07: Chimerex, Inc. Reports Q2 EPS of \$(0.39) vs \$(0.44) Est; Revenue of \$919.0M vs \$740.0K Est

Financial news for CMRX dated on 2014-06-23: Brean Capital Initiates Coverage on Chimerex, Inc. at Buy, Announces \$33.00 PT

Financial news for CMRX dated on 2014-05-21: Chimerix Prices 7.3M Share Offering at \$14.22/Share

Financial news for CMRX dated on 2014-05-09: Chimerex, Inc. Reports Q1 EPS of \$(0.39) vs \$(0.36) Est; Revenue of \$780.0K vs \$850.0K Est

Financial news for CMRX dated on 2014-03-15: Chimerix Thanks FDA for Collaboration in Developing Protocol to Treat Patients With Life-Threatening Adenovirus Infection

Financial news for CMRX dated on 2014-03-12: Chimerix Receives FDA Approval to Provide Brincidofovir to Josh Hardy

Financial news for CMRX dated on 2014-03-07: Chimerex, Inc. Reports Q4 EPS of \$(0.31) vs \$(0.41) Est; Revenue of \$879.0K vs \$1.19M Est

Financial news for CMRX dated on 2014-02-13: Canaccord Genuity Initiates Coverage on Chimerex, Inc. at Buy, Announces \$34.00 PT

Financial news for CMRX dated on 2013-11-26: Piper Jaffray Initiates Coverage on Chimerex, Inc. at Overweight, Announces \$33.00 PT

Financial news for CMRX dated on 2013-11-14: Chimerex Reports Q3 EPS of \$(0.26) vs \$(0.38) Est; Revenue of \$912.0K vs \$1.28M Est

Financial news for CMRX dated on 2013-09-26: Chimerix Says CMX001-201 Met Primary Goal in CMV Viremia/Disease Cut

Financial news for CMRX dated on 2013-09-11: Chimerix Presents Positive Brincidofovir Adenovirus Phase 2 Results

Financial news for CMRX dated on 2013-09-09: Chimerix Initiates Phase 3 SUPPRESS Trial of Brincidofovir

Financial news for CMRX dated on 2013-08-14: Chimerix Announces Positive Top Line Data From CMX001 Phase 2 Adenovirus Study

Financial news for CMRX dated on 2013-08-14: Chimerex, Inc. Reports Q2 EPS of \$(0.91) vs \$(0.40) Est; Revenue of \$808.0K vs \$1.91M Est

Financial news for CMRX dated on 2013-06-03: Chimerix, BARDA Extend Collaboration on Development of CMX001 Against Smallpox

Financial news for CMRX dated on 2013-05-07: William Blair Initiated Coverage on Chimerex, Inc. at Outperform, Announced \$28.00 PT

Financial news for CMRX dated on 2013-05-06: Cowen & Company Initiates Coverage on Chimerex, Inc. at Outperform

Financial news for CMRX dated on 2013-05-06: Lazard Capital Markets Initiates Coverage on Chimerex, Inc. at Buy, Announces \$32.00 PT

Financial news for CMRX dated on 2013-05-06: Morgan Stanley Initiates Coverage on Chimerex, Inc. at Overweight, Announces \$26.00 PT

Financial news for CMRX dated on 2013-04-01: Chimerix Files to Offer 6.1M Shares